Immunotec wins Gold Globee for research and development

Immunotec has won a Gold Globee® Award for Achievement in Research & Development in the 2026 Globee® Awards for Innovation. The recognition highlights the company’s decades of glutathione research, its growing patent portfolio and new work in neurological and neuropsychiatric science.

Why it matters: - The award spotlights a long-running research program that could shape future applications for Immunocal® and glutathione science. - Immunotec says its research has moved beyond nutrition into areas such as autism, traumatic brain injury, schizophrenia and Alzheimer’s-related markers. - The recognition may help validate the company’s scientific platform with customers, researchers and potential partners.

What happened: - Immunotec won a Gold Globee® Award for Achievement in Research & Development in the 18th Annual 2026 Globee® Awards for Innovation. - The Globee® Awards for Innovation are also known as the Golden Bridge Awards®. - The company is a global health and wellness firm with nearly three decades of experience in glutathione science and a portfolio of 81 patents. - CEO Mauricio Domenzain said the award honors the company’s long-term commitment to rigorous research and continued exploration of glutathione science.

The details: - Immunocal® is Immunotec’s flagship product. - Immunocal® is a patented, cysteine-rich whey protein isolate designed to provide cysteine, a building block for glutathione production. - Immunotec says its research platform spans more than four decades of scientific investigation. - The company says it has invested more than $25 million in research. - The research record includes 92 scientific publications and 26 blinded human trials. - Immunotec says its work has involved 275 researchers and 169 institutions across 20 countries. - The company’s intellectual property and research have expanded into neurological and neuropsychiatric areas. - In April 2024, Immunotec received a U.S. patent tied to the use of its cysteine-rich whey protein isolate in autism after a randomized, double-blind, placebo-controlled human study in young children. - In June 2026, Immunotec received two more U.S. patents covering resilience to traumatic brain injury and increased Reelin expression in the prefrontal cortex in schizophrenia. - A 2025 preclinical study in the Journal of Alzheimer’s Disease examined links among Immunocal, glutathione, Reelin and markers associated with Alzheimer’s disease. - The Globee® Awards say winners are chosen through a merit-based, score-driven process with participation from professionals around the world. - The Achievement in Research & Development category recognizes long-term investment in scientific discovery and technical experimentation. - Immunotec serves customers and independent Consultants across 30 global markets. - The company says more information is available at Immunotec.com.

Between the lines: - The award gives Immunotec a third-party signal that its research strategy is more than a marketing claim. - The patent activity suggests the company is trying to build a broader scientific identity around glutathione support, not just a single consumer product. - The mix of human studies, patents and preclinical work shows a research program trying to move from nutrition science into adjacent therapeutic questions.

What's next: - Immunotec says its research story is still being written. - The company is likely to keep expanding its publication, patent and collaboration footprint as it explores additional uses for Immunocal and glutathione science. - Further work in neurological and neuropsychiatric areas may be an important focus for future announcements.

The bottom line: - Immunotec’s Gold Globee adds outside recognition to a long-term research push that now reaches well beyond nutritional wellness.